ClonoMRD is an advanced next-generation sequencing (NGS) based assay that analyzes immunoglobulin (IG) gene rearrangements to identify and characterize clonal B-cell populations with high analytical precision. By defining dominant clonal sequences at diagnosis, ClonoMRD enables highly sensitive, sequence-specific minimal residual disease (MRD) tracking across treatment and follow-up, supporting evidence-based clinical decision-making in B-cell malignancies. Accurate assessment of B-cell clonality and minimal residual disease (MRD) is critical for the diagnosis, risk stratification, and long-term monitoring of B-cell malignancies. Conventional methods such as flow cytometry and PCR may have limitations in sensitivity for very low-level disease or track clonal evolution over time.
| Feature | Description | |
|---|---|---|
| NGS-based clonality analysis | Evaluates the B-cell repertoire to distinguish polyclonal (reactive) from clonal (mono, bi-, or oligoclonal) populations. | |
| High-sensitivity MRD detection | Detects residual disease down to 10⁻⁶ sensitivity. | |
| Comprehensive IG coverage | Targets IGH (FR1, FR2, FR3) and IGK rearrangements. | |
| SHM assessment | Provides somatic hypermutation status for prognostic insights. | |
| Longitudinal monitoring | Enables serial MRD tracking using the baseline dominant clone signature. | |
| Objective quantification | Quantifies MRD burden using sequence-based cell equivalents (% reads). |
TAT: 21 working days
Test Code: MGM3659
TAT: 21 working days
Test Code: MGM3660
Enables detection of minimal residual disease with sensitivity up to 10⁻⁶, supporting early identification of molecular relapse.
Analyses IGH (FR1, FR2, FR3) and IGK rearrangements to ensure broad detection of B-cell clonal populations.
Identifies dominant clone sequences at diagnosis and uses the same molecular signature for accurate longitudinal MRD monitoring.
Please share your details to get
in touch with our experts.
